ANNXAnnexon, Inc.
$3.99+30% 1Y
$3.99
$2.6852 weeks$6.96
ANNX in its own filings
Nothing in ANNX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
124
Events found in the filings · across 521 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 10-Q
- Record starts
- Oct 16, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity14 occurrences
- 2024-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones.Earnings release · press release
- Aug 10, 2026Director Resignation On August 10, 2026, Muneer Satter, a member of the board of directors (the “Board”) of Annexon, Inc. (the “Company”), notified the Company of his resignation as a member of the Board and as a member of the audit committee of the Board (the “Audit Committee”) and as chair of the nominating and …Director or officer change · Form 8-K
- Aug 6, 2026Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive.Other event · press release
- Jul 30, 2026On July 30, 2026 (the “Effective Date”), Annexon, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”)Material agreement entered · Form 8-K
- May 7, 2026Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones.Earnings release · press release
- Mar 30, 2026Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones.Earnings release · press release
- Feb 17, 2026On February 12, 2026, Thomas G. Wiggans, Chairman of the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
- Jan 14, 2026MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX ©2025 Annexon, Inc. All rights reserved.Regulation FD disclosure · press release
- Jan 12, 2026On January 12, 2026, Annexon, Inc. issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” announcing its 2026 strategic priorities and key milestones for its lead programs.Other event · Form 8-K
- Nov 14, 2025On November 12, 2025, Annexon, Inc. (the “Company ’) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, TD Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters listed therein (collectively, the “Underwriters”), to issue …Material agreement entered · Form 8-K
- Nov 10, 2025Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…